Generics - Oncology

Filter

Current filters:

Oncology

Popular Filters

51 to 75 of 91 results

MSF update on Novartis versus India, Supreme Court case

18-11-2012

Humanitarian health organization Medecins Sans Frontieres (MSF) says it continues to follow progress…

Asia-PacificGenericsGlivecLegalNovartisOncologyPatentsPharmaceutical

Survey reveals 98.9% of US physicians experienced cancer drug shortages in last 12 months

15-11-2012

The Community Oncology Alliance (COA), a US non-profit organization, announced the results of a drug…

GenericsHealthcareNorth AmericaOncologyPharmaceuticalPricing

India's Cipla cuts prices of three cancer drugs

12-11-2012

Following what Indian drugmaker Cipla (BSE: 500087) said was an "overwhelming response" on the price…

Asia-PacificcapecitabineCipladocetaxelerlotinibGenericsOncologyPatentsPfizerPharmaceuticalPricingSunitinib MalateSutent

Generics and biosimilars will lead to decline in colorectal cancer market from $8.3 billion in 2011 to $7.8 billion in 2021

04-11-2012

Through 2021, growth in the market for colorectal cancer (CRC) treatments will decline in the face of…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Biosimilar versions of MAbs for cancer forecast to garner sales of $4.9 billion in 2021

28-10-2012

While branded versions of monoclonal antibodies for cancer are expected to maintain sales of $6.7 million…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Hikma signs deal with GP Pharma for Lutrate 1 month in MENA region

22-10-2012

Jordanian drugmaker Hikma Pharmaceuticals (LSE: HIK) has signed a license and supply agreement for the…

GenericsGP PharmHikma PharmaceuticalsLicensingLutrateOncologyRest of the World

Another negative Indian patent ruling, this time for Pfizer's Sutent

08-10-2012

In yet another setback for research-based pharmaceutical companies, last week the Indian patent office…

Asia-PacificCiplaGenericsLegalNatco PharmaOncologyPatentsPfizerPharmaceuticalSutent

India's IPAB rejects Bayer's "stay petition" regarding Nexavar

18-09-2012

Over the weekend, the Intellectual Property Appellate Board (IPAB) of Chennai, India, has dismissed the…

Asia-PacificBayerGenericsLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

Bayer attempts to block generic Nexavar in India again slammed by MSF

04-09-2012

German drug major Bayer (BAYN: DE) yesterday headed to India's Intellectual Property Appellate Board…

Asia-PacificBayerGenericsLegalNexavarOncologyPatentsPharmaceutical

Indian hearings on Bayer Nexavar compulsory license delayed

22-08-2012

India's Intellectual Property Appellate Board (IPAB) in Chennai has postponed hearing the appeal by German…

Asia-PacificBayerGenericsLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

Hospira re-launches generic Eloxatin in USA

12-08-2012

US injectable drugs and infusion specialist Hospira (NYSE: HSP) last week announced the US re-launch…

GenericsMarkets & MarketingNorth AmericaOncology

Taiwan's ScinoPharm invests NT$1.1 billion in cytotoxic injectables facility

03-07-2012

Taiwan based active pharmaceutical ingredients maker ScinoPharm (TWSE: 1789) says it plans to invest…

Asia-PacificFinancialGenericsMarkets & MarketingOncologyScinoPharm

Indonesian $16 million NSCLC drugs market kept afloat by high-priced branded drugs

08-06-2012

Branded drugs for the treatment of non-small cell lung cancer (NSCLC) in Indonesia cost almost three…

Asia-PacificGenericsHealthcareMarkets & MarketingOncologyPharmaceutical

Merck KGaA collaborates with Dr Reddy's on biosimilars

07-06-2012

With the aim of capitalizing on the batch of patent expires for blockbuster biotechnology-based drugs…

BiotechnologyDr Reddy's LaboratoriesGenericsMarkets & MarketingMerck KGaAMerck SeronoOncologyResearch

51 to 75 of 91 results

Parexel

Parexel

Back to top